Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Circon VaporTrode II

This article was originally published in The Gray Sheet

Executive Summary

Circon VaporTrode II: Vaporizing electrode will be introduced "this month," Circon President and CEO Richard Auhll said Feb. 7 at the Piper Jaffray Medical Device Conference in New York City. The VaporTrode II, which will sell for $135, incorporates a new "scalloped" design "with longitudinal peaks," compared to the original VaporTrode's "barrel" design "with circumferential grooves," Auhll explained. Designed for use with Circon's Rotating Continuous Flow Resectoscope, the VaporTrode technology has been billed as a less costly treatment for benign prostatic hyperplasia than both transurethral resection of the prostate and laser vaporization. Auhll said that clinical reports indicate that VaporTrode II is "35-40% more effective" than the original device. The exec noted that Circon is expecting competition for the VaporTrode II, but added that the product has a "nice patent position" that the company will "defend...vigorously"...

You may also be interested in...

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts